Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks

... penetration of the antibiotic into the bacterial cell, completely changes the microbiological ... in the Fluidosomes(TM) is released into the bacterial cell. Additionally, our data indicate that bacterial rescue mechanisms that pump tobramycin out of the ...

Is Obesity an Oral Bacterial Disease?

... Groppo, S. Halem and E. Carpino measured salivary bacterial populations of overweight women. Saliva was ... with a body mass index between 27 and 32, and bacterial populations were measured by DNA probe analysis. ... median percentage difference of seven of the 40 bacterial species measured was greater than 2 percent in ...

Alcon Commences Phase 2 Clinical Trial of NovaBay's NVC-422 for Viral Conjunctivitis

... of conjunctivitis. Dual action against viral and bacterial conjunctivitis is important because when an ... which can result from either viral or bacterial infection, is an inflammation of the thin, clear ... up to three weeks or longer to clear on its own. bacterial conjunctivitis is caused by a variety of bacteria ...

Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases

... best-in-class drugs for the treatment of serious bacterial infections, announced today that the results of ... activity against drug-resistant Gram-positive bacterial pathogens including those resistant to Zyvox(R), ... treat serious infections caused by Gram-negative bacterial pathogens. For more information, visit ...

Nanoemulsion Kills Highly Resistant Bacteria Found in Patients With Cystic Fibrosis

... for patients infected with Burkholderia and other bacterial species that are resistant to all known ... frontline therapy against cystic fibrosis-related bacterial infections. But systemic drugs often fail to ... the bacteria or to penetrate the thick sputum and bacterial biofilms that coat the bacteria. The rising ...

Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections

... also an indicator of the increasing prevalence of bacterial infections caused by MRSA in our hospitals and ... safe and effective treatments for drug resistant bacterial infections in the hospital and in the community." ... activity against drug-resistant Gram-positive bacterial pathogens including those resistant to Zyvox(R), ...

Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin

... of agents for treatment of resistant bacterial infections. In fact, delafloxacin has been shown ... to levofloxacin in the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB). A 200 ... is a term used to group a wide range of severe bacterial skin infections involving the deeper soft tissue ...

Mpex Pharmaceuticals Announces Initiation of a Phase 2 Clinical Trial of Aerosol MP-376 in COPD

... quality of life and functional status. Chronic bacterial infection of the lower airways of patients with ... all of the common pathogens associated with bacterial exacerbations in COPD patients. By delivering the ... as a maintenance therapy for the prevention of bacterial exacerbations in patients with cystic fibrosis ...

Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting

... 2.0mg/L respectively. MIC90s for other relevant bacterial isolates in the study were 0.5mg/L and 2.0mg/L ... in various classes which are able to circumvent bacterial resistance mechanisms." Study Results The ... (uSSSI) is a term used to group a wide range of bacterial skin infections, including common dermatologic ...

Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

... most commonly used antiinfective agents to combat bacterial infections. However, the emergence of resistance ... presents a new and expanding market opportunity. bacterial resistance is causing many of the current ... novel compounds that can circumvent or block bacterial resistance. Paratek's lead compound, PTK 0796, is ...

Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis

... for P. aeruginosa at baseline. P. aeruginosa is a bacterial pathogen that is a leading cause of morbidity in ... aerosol administrations demonstrated rapid bacterial killing with no development of resistance ... systemic administration showed initial bacterial killing, but allowed for resistance development ...

Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA

... drugs for the treatment of serious bacterial infections, announced today that the results of ... Moiety of Prodrug TR-701, Against Selected bacterial Pathogens and Provisional Disk Test Criteria ... activity against drug-resistant gram-positive bacterial pathogens including those resistant to Zyvox(R). ...

Mpex Initiates a Phase 2 Clinical Trial of Aerosol MP-376 in the Treatment of Chronic Bacterial Infections in Cystic Fibrosis Patients

... antibiotic that has potent activity against key bacterial pathogens, including Pseudomonas aeruginosa. ... and that patients experienced a reduction in bacterial counts of Pseudomonas aeruginosa in sputum. The ... Phase 2 study will be microbiological (change in bacterial counts of Pseudomonas aeruginosa in sputum) over ...

Steroids Provide No Survival Benefit for Children With Bacterial Meningitis

... given to children who are hospitalized for bacterial meningitis do not provide a benefit in survival ... the meninges, the membrane lining the brain. The bacterial form is relatively rare in children, with an ... about eight in 100,000 in the U.S. However, bacterial meningitis is potentially life-threatening, and ...

Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701

... treatment of patients with serious Gram-positive bacterial infections, including those caused by MRSA and ... bacterial pathogens." "Because the majority of bacterial infections in the hospital are now caused by ... activity against drug-resistant Gram-positive bacterial pathogens including those resistant to ...

Replidyne Provides Strategic Update

... in clinical trials for faropenem in acute bacterial sinusitis (ABS) and community-acquired ... by inhibiting an essential enzyme in the bacterial cell called methionyl tRNA synthetase that blocks ... DNA replication is one of the essential steps in bacterial growth and remains an attractive target for ...

Paratek Pharmaceuticals Announces the Close of $40 Million Private Placement to Finance Programs to Combat MRSA Infections

... two antibiotics for the treatment of resistant bacterial infections such as those caused by ... to treat MRSA and other important bacterial infections in the physician's office setting. ... Paratek is well positioned to address problems of bacterial resistance." About Paratek Pharmaceuticals ...

Promising Data from Paratek Pharmaceuticals' MAR Inhibitor Program Presented in 'Late Breaker' Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy

... Technology Turns Off 'Master Switch' Underlying bacterial Infection and May Have Broad Use in Preventing Critical bacterial Infections BOSTON, Sept. 18 /PRNewswire/ -- ... in another animal model of serious bacterial infection. The article, titled, "Novel ...

New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA

... population carries S. aureus, the predominant bacterial species associated with skin infections. PVL, the ... group of bacteria that become red when the bacterial cells are treated using the Gram stain method. ... group of bacteria that become blue when the bacterial cells are treated with the Gram stain. This ...

Boston University Biomedical Engineers Find Chink in Bacteria's Armor

... antibiotics are used to target different bacterial functions: inhibiting DNA replication; ... that this underlying pathway exists. In studying bacterial response to a quinolone, an antibiotic that ... assembly lines that make energy for the bacterial cell, just as in the earlier study. They began to ...

Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections

... antibiotic with potent activity against drug-resistant, gram-positive bacterial pathogens including those resistant to linezolid, the only currently ... with lead candidates for serious infections caused by gram-negative bacterial pathogens. For more information, visit www.triusrx.com . ...

Advanced Life Sciences Announces Outcome of FDA's Anti-Infective Drugs Advisory Committee Review of Restanza(TM) (cethromycin)

... bacteria. Restanza's demonstrated potency and ability to overcome bacterial resistance may be due to its mechanism of action resulting in specificity for its bacterial target. In addition to its utility in CAP, Restanza is also being ...

CMC ICOS Biologics and Implicit Bioscience Ltd Announce IC14 Antibody Manufacturing Agreement and Patent License

... human CD14, an essential component of the innate inflammatory response to bacterial infection. CD14 triggers activation of the innate immune response to bacterial components including lipopolysaccharide via the Toll-like receptor (TLR) ...

Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine

... Streptococcus pneumoniae , or Pneumococcus, is a very common bacterial infection in both industrialized and developing countries. In particular, ... under the age of five years each year worldwide. It accounts for many bacterial Meningitis cases in adults and it is the most common cause of Bacteraemia, ...

FDA Submission of B-R-A-H-M-S MR-proANP Kryptor

... the Procalcitonin Kryptor, the company's test for the diagnosis of severe bacterial infections, introduced in the U.S. in early 2008. B-R-A-H-M-S is a ... Kryptor(R) test enables physicians to determine whether an infection is bacterial or viral in nature and provides actionable information on the severity of ...

Blue Light Destroys Antibiotic-Resistant Staph Infection - Results Reported in Photomedicine and Laser Surgery Journal

... free online at www.liebertpub.com/pho Antibiotic-resistant bacterial infections represent an important and increasing public health threat. At ... Staphylococcus aureus (MRSA) in Vitro ," the authors exposed bacterial colonies of MRSA to various doses of 470-nm light, which emits no UV ...

MicroPhage Successfully Completes Beta Trial for Rapid MRSA Test

... LONGMONT, Colo., Jan. 13 /PRNewswire/ -- A new bacterial identification test that rapidly identifies MRSA infections moved closer ... technology, a natural biologic process, for identifying bacterial infections. "Phages" are bacteria-specific viruses that multiply ...

Trius Doses First Patient in Antibacterial Phase 2 Trial

... antibiotic with potent activity against drug-resistant Gram-positive bacterial pathogens including those resistant to Zyvox(R). Trius has licensed ... programs being developed to treat infections caused by Gram negative bacterial pathogens. For more information, visit http://www.triusrx.com/ ...

InVitria Showcases Cell Culture Productivity Enhancers at BioProcess International

... media. (see http://www.Lacromin.com ) -- Lysobac -- Lysobac is a bacterial cell lysis agent that is more efficient and more consistent compared ... protein yield compared with mechanical cell lysis. Lysobac is used in bacterial fermentation to improve recombinant protein yields.(see ...

Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH

... only those DNA sequences essential for eliciting immune responses. The bacterial fermentation process typically used for DNA vaccines produces a closed ... influenza and other infectious diseases at Vical, are manufactured by bacterial fermentation in standardized equipment with a production time measured in ...

Clinically Proven Treatment Offers Help to Rosacea Sufferers

... hemisphere (rosacea) has not been addressed as a parasite, but as a bacterial infection." "If a person with rosacea is treated for a bacterial infection, their skin will clear up while they are on medication, but the ...

Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA

... within both hospital as well as community settings. The growing problem of bacterial resistance to many existing drugs also necessitates the development of new ... a new class of macrolide antibiotics, called Bicyclolides, which overcome bacterial resistance. Antibacterial focus areas include superbugs, respiratory tract ...

Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients

... on developing topical applications of its compounds to treat fungal, bacterial and inflammatory diseases. Anacor's most advanced product candidate is ... worldwide commercialization of novel systemic therapeutics for viral and bacterial diseases utilizing Anacor's boron-based chemistry. For more information ...

ActivBiotics Proposes Development Strategy for Its Novel Rifamycin Antibiotics

... therapy has been used as the treatment of choice for certain stubborn bacterial infections. Two prime examples are tuberculosis and gastric ulcer disease, ... against key pathogens, the NCEs may also be developed for the treatment of bacterial endocarditis, osteomyelitis, acute and chronic respiratory infections, ...

GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program

... stage -- its telavancin program focusing on treating serious Gram-positive bacterial infections with Astellas Pharma Inc., the Gastrointestinal Motility ... GlaxoSmithKline, and TD-1792 for the treatment of serious Gram-positive bacterial infections. By leveraging its proprietary insight of multivalency toward ...

Seal Shield Launches World's First Antibacterial, Dishwasher Safe Keyboard and Mouse for Infection Control

... which can be disinfected and washed in order to prevent the spread of bacterial infection. Unlike traditional antibacterial products, the SILVER ... among the primary cross contamination points for the spread of viruses and bacterial infections," states Bradley Whitchurch, Chief Executive Officer at Seal ...

New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections

... Gram-positive indicates a group of bacteria that become blue when the bacterial cells are treated with Gram stain. This response is based on the ... Gram-negative indicates a group of bacteria that become red when the bacterial cells are treated with Gram stain method. This response is based on ...

Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy

... cethromycin, a novel once-a-day antibiotic in response to the emerging bacterial resistance observed in the treatment of community acquired pneumonia ... marketplace and address the critical need for antibiotics that overcome bacterial resistance. Forward-Looking Statements Any statements contained in this ...

Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy

... cethromycin, a novel once-a-day antibiotic in response to the emerging bacterial resistance observed in the treatment of community acquired pneumonia ... marketplace and address the critical need for antibiotics that overcome bacterial resistance. Forward-Looking Statements Any statements contained in this ...

Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria

... daptomycin, and/or vancomycin, as well as strains of streptococci. bacterial isolates included S. aureus (n=35), coagulase-negative staphylococci ... of Oritavancin against a Broad Spectrum of Aerobic and Anaerobic bacterial Pathogens (E-1612, 12:15 p.m. CDT) -- Anti-Streptococcal Activity ...